LONDON (Reuters) - Drugmaker Shire said on Wednesday that its Lifitegrast treatment for adults with dry eye disease failed to meet one of two goals in a late-stage trial, the same result it saw in trial results in December. [ID:nL5N0JL1A5]
The drug met one goal for patient-reported symptoms of dry eye compared with placebo, the company said, but did not meet the second target based on signs of corneal staining.
Lifitegrast - a potential competitor for Allergan's Restasis, which is expected to have sales of around $900 million this year - is viewed as a key new product for Shire as it seeks to diversify its product line-up.
(Reporting by Paul Sandle; Editing by Brenda Goh)